Travoprost is a generic drug name and the active ingredient in drugs marketed in the U.S. under the brand names Izba, Travatan, and Travatan Z. The medication works by controlling fluid flow within the eye to maintain normal pressure. It relieves high pressure in the eye to help prevent blindness.
Travoprost has a molecular weight of 500.55g/mol and is clear oil - colorless to slightly yellow. It is quite insoluble in water, but highly soluble in methanol, acetonitrile, chloroform, and octanol.
Travoprost belongs to the drug class ophthalmic glaucoma agents. Travatan Z (travoprost), which is the latest formulation of Travatan, is FDA approved and received its first approval on September 21st, 2016.
In Travatan Z, the benzalkonium chloride preservative is replaced with the gentler ionic, buffered Sofzia. The disadvantage of the replaced chemical is that it can react with contact lenses.
Some unwanted effects could arise from the use of this medicine.
Other side effects of travoprost are not critical and do not require immediate medical attention. As the patient's body adjusts to the medication, these effects go away. However, in cases where these symptoms become bothersome or refuse to go away, the advice of a doctor, nurse or pharmacist can be sought. The healthcare professionals can give tips on how to minimize or altogether prevent the unwanted effects.
The recommended dosage is one drop to the affected eye once a day in the evening.
Travoprost ophthalmic solution should not be administered more than once in a day as increasing the frequency of application of prostaglandin analogs lowers their effect of reducing intraocular pressure.
After administration of travoprost solution, the intraocular pressure lowering effect begins in two hours and reaches a maximum in 12 hours.
A travoprost ophthalmic solution may be used concomitantly with other topical products to reduce intraocular pressure. However, administration of such solutions must be done at least 5 minutes apart and never at the same time.
The safety and efficacy of this drug have been proven for persons 16 years and under. There are no suggested dose adjustments for patients with renal and liver impairment or those undergoing dialysis.
An excess solution of travoprost ophthalmic that may overflow onto the skin should be wiped away to prevent the darkening of the skin that regularly contacts the solution.
The eyelids should be gently closed after administration of the drug. This may help reduce systemic absorption of the topically administered ophthalmic solution.
The medicine should be regularly used, at the same time each day and continued even if there are no symptoms. Most people with high pressure in the eyes show no signs.
If a dose is missed, it should be used as soon as possible. However, if the missed treatment can only be taken close to the time of the next dose, it should not be considered. A double dose should never be taken to make up for a missed one.
Here is how to administer travoprost solution:
Travoprost has very few interactions that are clinically significant. It interacts with one drug (2 generic and brand names) and three diseases.
Travoprost has moderate interactions with the following medications:
It is implied that the interactions are moderately clinically significant and combinations are to be avoided or used only under exceptional circumstances.
Travoprost has the following disease interactions:
Studies done on animals have shown teratogenic results. Well-controlled adequate studies on women are unavailable.
The AU TGA has listed it in pregnancy Category B3. These are drugs that can only be consumed by a partial number of women who can bear children as well as those already pregnant without an increase in the incidence of malformations and other indirect and direct deleterious effects on the fetus. Other animal studies reveal an increase in the frequency of fetal damage which would not necessarily be the case in humans.
U.S. FDA pregnancy category C: Studies on animals show an adverse effect on the fetus, but there are no well-controlled and adequate studies on pregnant women. Potential benefits of this drug to pregnant women may warrant use of the drug despite the likely risks.
Travoprost is contraindicated for use during pregnancy in Australia. In the U.S. and UK, use of the drug is allowed during pregnancy if the benefits to the woman outweigh the risks to the fetus.
Women who are trying to get pregnant or are already pregnant should avoid direct exposure to travoprost solution.
There is no information on if this drug is passed into human milk, but it is passed into animal milk. Use of this medication during breastfeeding should be avoided unless there are no other alternatives. The effects it would have on a nursing infant are unknown.
Travoprost should be useful for indicated conditions. If a patient experiences worsening symptoms or no improvement after using this medicine, a doctor should be notified immediately. The patient should never attempt to increase the dose or decide on a course of action on their own.
Taking another person's drugs should also not be done. Even if the drugs are indicated for the same conditions, a patient should never decide to use what they think works. Only a physician and other healthcare professionals have the expertise to consider all available information and prescribe medicine.
The doctor should similarly be informed of everything the patient is using such as other drugs including OTC medications, natural products, vitamins, and minerals. This is important to help the doctor determine any possible interactions. It should never be assumed that vitamins and natural products are safe to mix with any drug.
A patient can find out anything they need to know about a drug from the product information leaflet that comes with any drug package. The patient should also discuss issues and concerns about their medication with their pharmacist and healthcare provider.
The information contained here is not in any way meant to replace the advice of a healthcare provider. This information is a summary on travoprost and does not in any way endorse the drug as approved, effective or safe for any condition or patient. It should be used for general purposes only, as not all information about the drug is included here.